Kodiak Sciences Inc. (NasdaqGM: KOD)
Health Care · Biotechnology · US
$39.46
+6.02% today · +307.6% 1Y
Kodiak Sciences Inc. (NasdaqGM: KOD) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.48B and employs 141 people.
Over the last twelve months the share price has gained 307.6%, trading between 8.29 and 47.84.
Tweenvest scores Kodiak Sciences Inc. across four factors: quality 26/100. Its strongest factor is quality.
KOD price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.48B
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -4.18
- Dividend yield
- —
- Beta (5Y)
- 2.20
- 52-week high
- $47.84
- 52-week low
- $8.29
- Avg volume (3M)
- —
- Shares outstanding
- 62.72M
- Employees
- 141
- Next earnings
- —
About Kodiak Sciences Inc.
Kodiak Sciences Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to discovering, advancing, and bringing to market treatments for various conditions affecting the retina. Their primary drug candidate, KSI-301, is an anti-vascular endothelial growth factor (anti-VEGF) antibody biopolymer. This compound is currently undergoing Phase IIb/III clinical trials, targeting illnesses such as wet age-related macular degeneration (AMD), diabetic macular edema, previously untreated macular edema resulting from retinal vein occlusion, and non-proliferative diabetic retinopathy. In its earlier, preclinical development pipeline, the company is also working on KSI-501, a bispecific conjugate designed for retinal conditions involving inflammation, and KSI-601, a triplet inhibitor aimed at addressing dry AMD. Established in 2009, this Palo Alto, California-based company operated under the name Oligasis, LLC before rebranding as Kodiak Sciences Inc. in September 2015.
- ISIN
- US50015M1099
- Founded
- 2009
- Listed since
- Oct 4, 2018
- Exchange
- Nasdaq Global Market
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $469.68B | $265.75 | -0.02% |
| Amgen Inc.NasdaqGS: AMGN | $239.09B | $441.55 | -0.16% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $184.47B | $148.77 | +1.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $140.13B | $552.00 | -0.15% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.24B | $832.63 | -0.11% |
| argenx SEENXTBR: ARGX | $64.17B | €898.00 | +2.14% |
| Moderna, Inc.NasdaqGS: MRNA | $63.41B | $157.87 | -0.60% |
| CSL LimitedASX: CSL | $59.49B | AU$173.64 | +2.68% |
Figures last refreshed Aug 18, 2026.